Boteng: net profit in the first half of the year increased by 60% - 70% year on year
According to the announcement of Boteng, the net profit in the first half of 2021 is expected to be 210 million yuan – 223 million yuan, with a year-on-year growth of 60% - 70%. Under the background of steady growth of global pharmaceutical R & D pipeline and increasing trend of pharmaceutical R & D outsourcing, the company has continuously consolidated the achievements of cdmo strategic transformation, continuously expanded and enriched product pipeline, continuously improved technical capability and product delivery capability, and continuously improved the company's ability to obtain orders. In the first half of 2021, the company expects to achieve a 30% - 40% increase in operating revenue compared with the same period last year.
This text is a result of machine translation.
Related companies：
In-depth
Briefing May 19, 2022 11:34 AM
· Financials
The index recovered, and the gem index and Shanghai index once turned red
May 11, 2023 05:07 PM
Jan 06, 2023 08:30 AM
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Briefing Mar 13, 2022 04:38 PM
Dongfang Yuhong: adjust the prices of some main products of the company, among which the asphalt coiled material is increased by 15% - 20%.
Donghua Technology: pre winning the EPC project of ammonium dihydrogen phosphate project for battery
Insight
Technology
Consumer Electronics: ESG Emerging as a Hidden Highlight
In the face of the global consumer electronics industry in the cold, the future is more than relying on technological iteration and consumer upgrades, ESG and sustainable is providing new possibilities for the development of the industry.
Nov 30, 2023 10:11 PM
Insight
Market shock consolidation, public offering and private placement increased positions simultaneously
Briefing Dec 20, 2021 08:58 AM
Bufeng international calls out the list of Hong Kong stocks under Shenzhen Hong Kong stock connect
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth
Insight
In-depth